FFO
ELTX icon

Fortitude Family Office’s Elicio Therapeutics ELTX Stock Holding History

Fortitude Family Office’s Portfolio ELTX Stock Details ELTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-93
Closed -$740 – 1944
2025
Q4 		$740 Buy
+93
New +$844 ﹤0.01% 1566

Other funds holding ELTX

KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Fortitude Family Office's ELTX Position: Q1 2026 in Review

Fortitude Family Office sold out of Elicio Therapeutics (ELTX) in Q1 2026, closing a stake of 93 shares — an estimated $740 sold.

Fortitude Family Office first reported a position in ELTX in Q4 2025 and held it in 1 quarter. The position peaked at $740 in Q4 2025. 47 funds tracked by Wall St. Rank hold ELTX as of Q1 2026.

  • Fortitude Family Office reported no remaining Elicio Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Fortitude Family Office sold 93 Elicio Therapeutics shares in Q1 2026, an estimated $740.
  • Fortitude Family Office first reported a position in Elicio Therapeutics in Q4 2025 and held it in 1 quarter.
  • Fortitude Family Office's Elicio Therapeutics position peaked at $740 in Q4 2025.
  • 47 funds tracked by Wall St. Rank held Elicio Therapeutics as of Q1 2026.

Based on Fortitude Family Office's 13F filing for Q1 2026, filed 16 Apr 2026.